Back
Halozyme Therapeutics Stock Price Chart
This Tech Company Grew 32,481%...
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
57
HALO
Halozyme Therapeutics
Last Price:
$53.30
Seasonality Move:
2.59%
7 Day Trial
ALL ACCESS PASS
$
7
-
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing buying pressure, which is a positive indicator for future bullish movement.
Halozyme Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 58.68 | Sell |
| 20-day SMA: | 59.36 | Sell |
| 50-day SMA: | 60.81 | Sell |
| 200-day SMA: | 56.35 | Sell |
| 8-day EMA: | 55.37 | Sell |
| 20-day EMA: | 58.4 | Sell |
| 50-day EMA: | 59.26 | Sell |
| 200-day EMA: | 55.4 | Sell |
Halozyme Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -1.93 | Sell |
| Relative Strength Index (14 RSI): | 39.77 | Sell |
| Chaikin Money Flow: | 2565199 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (54.26 - 64.74) | Sell |
| Bollinger Bands (100): | (52.42 - 62.84) | Sell |
Halozyme Therapeutics Technical Analysis
| May 5 | May 6 | May 7 | May 8 | May 9 | May 12 | May 13 | May 14 | May 15 | May 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| May | ||||||||||
| 05 | 06 | 07 | 08 | 09 | 12 | 13 | 14 | 15 | 16 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Halozyme Therapeutics Stock
Is Halozyme Therapeutics Stock a Buy?
-
Halozyme Therapeutics share price is 52.02 while HALO 8-day simple moving average is 58.68, which is a Sell signal.
-
The stock price of HALO is 52.02 while Halozyme Therapeutics 20-day SMA is 59.36, which makes it a Sell.
-
Halozyme Therapeutics 50-day simple moving average is 60.81 while HALO share price is 52.02, making it a Sell technically.
-
HALO stock price is 52.02 and Halozyme Therapeutics 200-day simple moving average is 56.35, creating a Sell signal.
HALO Technical Analysis vs Fundamental Analysis
Buy
57
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a BuyThe current Halozyme Therapeutics [HALO] share price is $52.02. The Score for HALO is 57, which is 14% above its historic median score of 50, and infers lower risk than normal.
Halozyme Therapeutics Stock Info
Market Cap:
6.4B
Price in USD:
52.02
Share Volume:
4M
Halozyme Therapeutics 52-Week Range
52-Week High:
70.51
52-Week Low:
42.01
Buy
57
Halozyme Therapeutics (HALO)
is a Buy
Halozyme Therapeutics Share Price Forecast
-
What is the Halozyme Therapeutics stock price today?The Halozyme Therapeutics stock price is 52.02 USD today.
-
Will HALO stock go up or go down?Halozyme Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Halozyme Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Halozyme Therapeutics is not overvalued.
Is Halozyme Therapeutics Stock a Buy?
-
Halozyme Therapeutics share price is 52.02 while HALO 8-day exponential moving average is 55.37, which is a Sell signal.
-
The stock price of HALO is 52.02 while Halozyme Therapeutics 20-day EMA is 58.40, which makes it a Sell.
-
Halozyme Therapeutics 50-day exponential moving average is 59.26 while HALO share price is 52.02, making it a Sell technically.
-
HALO stock price is 52.02 and Halozyme Therapeutics 200-day simple moving average is 55.40, creating a Sell signal.
Fundamental Analysis of Halozyme Therapeutics
Is Halozyme Therapeutics a good investment?
-
Analysts estimate an earnings increase this quarter of $0.41 per share, a decrease next quarter of $0.06 per share, an increase this year of $1.19 per share, and an increase next year of $1.27 per share.
Technical Analysis of Halozyme Therapeutics
Should I short Halozyme Therapeutics stock?
-
HALO Moving Average Covergence Divergence (MACD) indicator is -1.93, suggesting Halozyme Therapeutics is a Sell
-
Halozyme Therapeutics Relative Strength Index (RSI) is 39.77, which suggest Halozyme Therapeutics is oversold
-
The Bollinger Bands (25) for Halozyme Therapeutics is (54.26 - 64.74), which suggest Halozyme Therapeutics is a Sell
-
The Bollinger Bands (100) for Halozyme Therapeutics is (52.42 - 62.84), which suggest Halozyme Therapeutics is a Sell
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.